• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫检查点抑制剂在头颈部鳞状细胞癌中的应用：现状与未来展望。

Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives.

机构信息

Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.

Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.

出版信息

Future Oncol. 2024;20(23):1695-1711. doi: 10.1080/14796694.2024.2362612. Epub 2024 Jun 18.

DOI:10.1080/14796694.2024.2362612
PMID:38889284
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11485897/
Abstract

Immune checkpoint inhibitors are licensed for use in patients with unresectable, recurrent or metastatic head and neck squamous cell carcinoma. Multiple published and ongoing trials are assessing efficacy in the curative management of patients in the concomitant, neoadjuvant and/or adjuvant settings, as well as part of multimodality treatment in patients with metastatic disease. This review evaluates the evidence for use of immune checkpoint inhibitors in all stages of head and neck squamous cell carcinoma and considers future approaches.

摘要

免疫检查点抑制剂已获准用于治疗不可切除、复发性或转移性头颈部鳞状细胞癌患者。多项已发表和正在进行的临床试验正在评估免疫检查点抑制剂在同期、新辅助和/或辅助治疗可切除患者，以及转移性疾病患者的多模式治疗中的疗效。本文综述了免疫检查点抑制剂在头颈部鳞状细胞癌各期的应用证据，并探讨了未来的方法。

相似文献

1
Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives.免疫检查点抑制剂在头颈部鳞状细胞癌中的应用：现状与未来展望。
Future Oncol. 2024;20(23):1695-1711. doi: 10.1080/14796694.2024.2362612. Epub 2024 Jun 18.
2
Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.增强程序性细胞死亡蛋白1轴抑制在头颈部鳞状细胞癌中的作用：联合免疫疗法
Cancer Treat Rev. 2021 Jun;97:102192. doi: 10.1016/j.ctrv.2021.102192. Epub 2021 Mar 24.
3
Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer.局部晚期和高危头颈部癌免疫治疗试验的现状。
Immunotherapy. 2021 Aug;13(11):931-940. doi: 10.2217/imt-2021-0048. Epub 2021 Jun 8.
4
Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review.新辅助免疫检查点抑制剂治疗局部晚期头颈部鳞状细胞癌的进展：叙述性综述。
Int Immunopharmacol. 2024 Jun 15;134:112200. doi: 10.1016/j.intimp.2024.112200. Epub 2024 May 13.
5
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).癌症免疫治疗学会关于免疫治疗头颈部鳞状细胞癌（HNSCC）的共识声明。
J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5.
6
Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations.将检查点抑制剂引入头颈部癌症的治疗环境：经验教训，未来的考虑。
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-16. doi: 10.1200/EDBK_351336.
7
Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment.少即是多：探索新辅助免疫治疗作为头颈部鳞状细胞癌治疗的降级策略。
Cancer Lett. 2024 Aug 28;598:217095. doi: 10.1016/j.canlet.2024.217095. Epub 2024 Jul 2.
8
Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.头颈部癌症中免疫检查点抑制剂的治疗方法及PD-L1作为生物标志物的作用
Cancer Control. 2021 Jan-Dec;28:10732748211004878. doi: 10.1177/10732748211004878.
9
Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.癌症类型和组织学影响皮肤免疫治疗的毒性：一项多机构队列研究。
Br J Dermatol. 2024 Jun 20;191(1):117-124. doi: 10.1093/bjd/ljae053.
10
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy.抗PD-1/PD-L1免疫治疗后复发或转移性头颈部鳞状细胞癌的管理方法
Cancer Treat Rev. 2025 May;136:102938. doi: 10.1016/j.ctrv.2025.102938. Epub 2025 Apr 10.

引用本文的文献

1
The landscape of cyclin-dependent kinase 4/6 inhibitors in solid malignancies: emphasis on immunotherapy combinatorial strategies.细胞周期蛋白依赖性激酶4/6抑制剂在实体恶性肿瘤中的应用前景：重点关注免疫治疗联合策略
Med Oncol. 2025 Aug 26;42(10):447. doi: 10.1007/s12032-025-02996-8.

本文引用的文献

1
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
2
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.个体化新抗原疗法mRNA-4157（V940）联合帕博利珠单抗与帕博利珠单抗单药治疗可切除黑色素瘤（KEYNOTE-942）：一项随机2b期研究
Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18.
3
Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.在晚期实体瘤患者中，联合使用检查点抑制剂和立体定向体部放疗：CHEERS 阶段 2 随机临床试验。
JAMA Oncol. 2023 Sep 1;9(9):1205-1213. doi: 10.1001/jamaoncol.2023.2132.
4
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.纳武利尤单抗联合伊匹单抗对比纳武利尤单抗单药治疗头颈部复发或转移性鳞状细胞癌的疗效和安全性：Ⅱ期 CheckMate 714 随机临床试验。
JAMA Oncol. 2023 Jun 1;9(6):779-789. doi: 10.1001/jamaoncol.2023.0147.
5
Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner.免疫原性低分割放射治疗以髓系来源抑制细胞（MDSC）依赖的方式增强头颈部鳞状细胞癌对 PD-L1 治疗的敏感性。
Br J Cancer. 2023 Jun;128(11):2126-2139. doi: 10.1038/s41416-023-02230-0. Epub 2023 Mar 28.
6
Exploration of prognostic biomarkers in head and neck squamous cell carcinoma microenvironment from TCGA database.利用TCGA数据库对头颈部鳞状细胞癌微环境中的预后生物标志物进行探索。
Ann Transl Med. 2023 Feb 28;11(4):163. doi: 10.21037/atm-22-6481.
7
Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial.度伐利尤单抗联合西妥昔单抗治疗复发性或转移性头颈部鳞状细胞癌患者：一项开放标签、非随机、Ⅱ期临床试验。
Clin Cancer Res. 2023 May 15;29(10):1906-1915. doi: 10.1158/1078-0432.CCR-22-3886.
8
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.度伐利尤单抗联合或不联合曲美木单抗对比EXTREME方案作为复发性或转移性头颈部鳞状细胞癌一线治疗的疗效：KESTREL，一项随机、开放标签的III期研究。
Ann Oncol. 2023 Mar;34(3):262-274. doi: 10.1016/j.annonc.2022.12.008. Epub 2022 Dec 16.
9
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.帕博利珠单抗与西妥昔单抗联合放疗用于不适合顺铂治疗的局部晚期头颈部鳞状细胞癌患者（GORTEC 2015 - 01 PembroRad）：一项多中心、随机、II期试验
Ann Oncol. 2023 Jan;34(1):101-110. doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28.
10
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.纳武利尤单抗联合伊匹木单抗对比 EXTREME 方案作为复发/转移性头颈部鳞癌一线治疗：CheckMate 651 的最终结果。
J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6.